Jinyu Bio-Technology Co (SHSE:600201) Piotroski F-Score: 8 (As of Jun. 28, 2026) — 60% Above Median


SHSE:600201 Jinyu Bio-Technology Co Ltd SHSE:600201
68 GF Score
Price ¥11.44
GF Value ¥8.19
Valuation Significantly Overvalued
! 5 Warning Signs
View Full Analysis

What is Jinyu Bio-Technology Co Piotroski F-Score?

Jinyu Bio-Technology Co SHSE:600201 -5.30% 68 Piotroski F-Score is 8 as of Jun. 28, 2026, which is 60% above its 10-year median of 5.00. GuruFocus rates SHSE:600201 with a GF Score™ of 68/100 and a GF Value™ of ¥8.19 (Significantly Overvalued). The stock has 5 warning signs investors should review. Among 1,340 Biotechnology companies, Jinyu Bio-Technology Co ranks better than 99.33% on this metric.

Good Sign:

Piotroski F-Score is 8, indicates a very healthy situation.

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Jinyu Bio-Technology Co has an F-score of 9. It is a good or high score, which usually indicates a very healthy situation.

The historical rank and industry rank for Jinyu Bio-Technology Co's Piotroski F-Score or its related term are showing as below:

SHSE:600201' s Piotroski F-Score Range Over the Past 10 Years
Min: 2   Med: 5   Max: 9
Current: 8

During the past 13 years, the highest Piotroski F-Score of Jinyu Bio-Technology Co was 9. The lowest was 2. And the median was 5.

Jinyu Bio-Technology Co  (SHSE:600201) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


Jinyu Bio-Technology Co Piotroski F-Score Related Terms


Jinyu Bio-Technology Co Piotroski F-Score Historical Data

* Premium members only.

The historical data trend for Jinyu Bio-Technology Co's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Jinyu Bio-Technology Co Piotroski F-Score Chart

Jinyu Bio-Technology Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Piotroski F-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only 4.00 4.00 7.00 5.00 6.00

Jinyu Bio-Technology Co Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Piotroski F-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.00 5.00 4.00 6.00 8.00

SHSE:600201 vs VRTX, REGN, ALNY: Piotroski F-Score Comparison

For the Biotechnology subindustry, Jinyu Bio-Technology Co's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Jinyu Bio-Technology Co Piotroski F-Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Jinyu Bio-Technology Co's Piotroski F-Score distribution charts can be found below:

* The bar in red indicates where Jinyu Bio-Technology Co's Piotroski F-Score falls into.


SHSE:600201
68GF Score
Jinyu Bio-Technology Co Ltd SHSE:600201
Piotroski F-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Mar26) TTM:Last Year (Mar25) TTM:
Net Income was -16.057 + 100.889 + -61.201 + 80.643 = ¥104 Mil.
Cash Flow from Operations was 62.725 + 102.682 + 124.491 + 11.408 = ¥301 Mil.
Revenue was 267.996 + 422.837 + 354.008 + 346.463 = ¥1,391 Mil.
Gross Profit was 131.992 + 237.977 + 185.859 + 185.296 = ¥741 Mil.
Average Total Assets from the begining of this year (Mar25)
to the end of this year (Mar26) was
(6698.923 + 6571.034 + 6734.467 + 6611.572 + 6536.935) / 5 = ¥6630.5862 Mil.
Total Assets at the begining of this year (Mar25) was ¥6,699 Mil.
Long-Term Debt & Capital Lease Obligation was ¥0 Mil.
Total Current Assets was ¥2,375 Mil.
Total Current Liabilities was ¥648 Mil.
Net Income was 17.332 + 46.622 + -60.556 + 76.481 = ¥80 Mil.

Revenue was 263.83 + 359.073 + 284.651 + 351.573 = ¥1,259 Mil.
Gross Profit was 142.815 + 191.234 + 130.563 + 191.697 = ¥656 Mil.
Average Total Assets from the begining of last year (Mar24)
to the end of last year (Mar25) was
(6920.701 + 6931.064 + 6903.124 + 6764.669 + 6698.923) / 5 = ¥6843.6962 Mil.
Total Assets at the begining of last year (Mar24) was ¥6,921 Mil.
Long-Term Debt & Capital Lease Obligation was ¥1 Mil.
Total Current Assets was ¥2,099 Mil.
Total Current Liabilities was ¥674 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Jinyu Bio-Technology Co's current Net Income (TTM) was 104. ==> Positive ==> Score 1.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Jinyu Bio-Technology Co's current Cash Flow from Operations (TTM) was 301. ==> Positive ==> Score 1.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (Mar25)
=104.274/6698.923
=0.01556579

ROA (Last Year)=Net Income/Total Assets (Mar24)
=79.879/6920.701
=0.01154204

Jinyu Bio-Technology Co's return on assets of this year was 0.01556579. Jinyu Bio-Technology Co's return on assets of last year was 0.01154204. ==> This year is higher. ==> Score 1.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

Jinyu Bio-Technology Co's current Net Income (TTM) was 104. Jinyu Bio-Technology Co's current Cash Flow from Operations (TTM) was 301. ==> 301 > 104 ==> CFROA > ROA ==> Score 1.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Mar26)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Mar25 to Mar26
=0.148/6630.5862
=2.232E-5

Gearing (Last Year: Mar25)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Mar24 to Mar25
=0.767/6843.6962
=0.00011207

Jinyu Bio-Technology Co's gearing of this year was 2.232E-5. Jinyu Bio-Technology Co's gearing of last year was 0.00011207. ==> This year is lower or equal to last year. ==> Score 1.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Mar26)=Total Current Assets/Total Current Liabilities
=2375.14/648.312
=3.66357556

Current Ratio (Last Year: Mar25)=Total Current Assets/Total Current Liabilities
=2098.517/674.37
=3.11181844

Jinyu Bio-Technology Co's current ratio of this year was 3.66357556. Jinyu Bio-Technology Co's current ratio of last year was 3.11181844. ==> This year's current ratio is higher. ==> Score 1.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

Jinyu Bio-Technology Co's number of shares in issue this year was 0. Jinyu Bio-Technology Co's number of shares in issue last year was 0. ==> There is smaller number of shares in issue this year, or the same. ==> Score 1.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=741.124/1391.304
=0.53268301

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=656.309/1259.127
=0.5212413

Jinyu Bio-Technology Co's gross margin of this year was 0.53268301. Jinyu Bio-Technology Co's gross margin of last year was 0.5212413. ==> This year's gross margin is higher. ==> Score 1.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (Mar25)
=1391.304/6698.923
=0.2076907

Asset Turnover (Last Year)=Revenue/Total Assets at the Beginning of Last Year (Mar24)
=1259.127/6920.701
=0.18193634

Jinyu Bio-Technology Co's asset turnover of this year was 0.2076907. Jinyu Bio-Technology Co's asset turnover of last year was 0.18193634. ==> This year's asset turnover is higher. ==> Score 1.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=1+1+1+1+1+1+1+1+1
=9

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Jinyu Bio-Technology Co has an F-score of 9. It is a good or high score, which usually indicates a very healthy situation.

Frequently Asked Questions Learn more about Piotroski F-Score →
What does a Piotroski F-Score of 8 mean?
Jinyu Bio-Technology Co (SHSE:600201) has a Piotroski F-Score of 8 as of Jun. 28, 2026. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on Jinyu Bio-Technology Co and its competitors. This is 60% above median its historical median of 5.00. Over the past decade, Jinyu Bio-Technology Co's Piotroski F-Score has ranged from 2.00 to 9.00. According to the industry distribution chart, Jinyu Bio-Technology Co ranks #9 out of 1340 companies in the Biotechnology industry, placing it in the top 0.7%.
Is Jinyu Bio-Technology Co's Piotroski F-Score too high?
Jinyu Bio-Technology Co's current Piotroski F-Score of 8 is 60% above median its 10-year median of 5.00. Over the past 10 years, this metric has ranged from a low of 2.00 to a high of 9.00. The Biotechnology industry median Piotroski F-Score is 3.00. Jinyu Bio-Technology Co's value of 8 is 166.7% above this industry median. Based on the distribution chart, Jinyu Bio-Technology Co ranks #9 out of 1340 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Jinyu Bio-Technology Co has a GF Score™ of 68/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Jinyu Bio-Technology Co's Piotroski F-Score compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Jinyu Bio-Technology Co ranks #9 out of 1340 companies for Piotroski F-Score. This places Jinyu Bio-Technology Co in the top 1% of its industry — outperforming the majority of peers. The industry median Piotroski F-Score is 3.00. Jinyu Bio-Technology Co's value of 8 is 166.7% above this benchmark. Historically, Jinyu Bio-Technology Co's own Piotroski F-Score has ranged from 2.00 to 9.00 over the past decade. While the company's 10-year median is 5.00 vs. the industry median of 3.00, Jinyu Bio-Technology Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Piotroski F-Score for a Biotechnology company?
The median Piotroski F-Score among Biotechnology companies is 3.00, based on 1,340 companies in the industry. Companies in the top quartile (top 25%) have a Piotroski F-Score significantly above this median, while those in the bottom quartile fall well below. However, Piotroski F-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Jinyu Bio-Technology Co's current Piotroski F-Score of 8 is 166.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Piotroski F-Score mean?
A high Piotroski F-Score can signal that a stock is expensive relative to its fundamentals. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on Jinyu Bio-Technology Co and its competitors. For the Biotechnology industry, the median Piotroski F-Score is 3.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Jinyu Bio-Technology Co's current Piotroski F-Score is 8, which is 60% above median its own 10-year median of 5.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Jinyu Bio-Technology Co stock overvalued right now?
Based on GuruFocus' analysis, Jinyu Bio-Technology Co (SHSE:600201) is currently considered Significantly Overvalued. The stock's GF Value™ is ¥8.19, compared to a current price of ¥11.44 — trading 39.7% above its estimated fair value. The current Piotroski F-Score is 8, which is 60% above median its 10-year median of 5.00 and 166.7% above the Biotechnology industry median of 3.00. Jinyu Bio-Technology Co's overall GF Score™ is 68/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Piotroski F-Score calculated?
Piotroski F-Score is calculated from a company's financial statements. For Jinyu Bio-Technology Co (SHSE:600201), the current Piotroski F-Score is 8 as of Jun. 28, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Jinyu Bio-Technology Co (SHSE:600201) Overvalued in 2026?

Based on GuruFocus' analysis, Jinyu Bio-Technology Co stock appears to be overvalued. The current stock price of ¥11.44 is trading 39.7% above its estimated GF Value™ of ¥8.19. GuruFocus considers Jinyu Bio-Technology Co to be Significantly Overvalued.

Key valuation signals for SHSE:600201:

  • Piotroski F-Score: 8 (60% above median its 10-year median of 5.00)
  • GF Value™: ¥8.19 vs. price of ¥11.44 (39.7% above fair value)
  • GF Score™: 68/100 with 5 warning signs
  • Industry Position: 166.7% above the Biotechnology median (#9 of 1340)

No single metric tells the full story. See the SHSE:600201 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Jinyu Bio-Technology Co Business Description

Address No.1, Jinyu Street, Shaeryu Industrial Park, Economic and Technological Development Zone, Inner Mongolia Autonomous Region, Hohhot, CHN, 010030
Jinyu Bio-Technology Co Ltd is engaged in the development and sales of veterinary biological products. Its products are used for pigs, poultry, pets, and ruminants.
68GF Score

Get the complete analysis for SHSE:600201

Piotroski F-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

¥11.44
Price
¥8.19
GF Value